Reducing the risk of stroke in type 2 diabetes: Pathophysiological and therapeutic perspectives

Journal of Neurology

Volumn 256, Issue 10, 2009, Pages 1603-1619

  Sander, Dirk ^a,b   Kearney, Mark T ^c  

^a Medical Park Hospital   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

Cardiovascular disease; Risk factors; Stroke; Systematic review; Type 2 diabetes

Indexed keywords

ACETYLSALICYLIC ACID; AMLODIPINE; ANTICOAGULANT AGENT; ANTIHYPERTENSIVE AGENT; ATENOLOL; ATORVASTATIN; CALCIUM ANTAGONIST; CAPTOPRIL; CHLORTALIDONE; CILOSTAZOL; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FENOFIBRATE; FOSINOPRIL; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDAPAMIDE PLUS PERINDOPRIL; INSULIN; IRBESARTAN; LOSARTAN; METFORMIN; PIOGLITAZONE; PLACEBO; PRAVASTATIN; RAMIPRIL; SIMVASTATIN; SULFONYLUREA; TELMISARTAN; UNINDEXED DRUG; WARFARIN;

ARTERIAL WALL THICKNESS; ATHEROSCLEROSIS; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISEASE ASSOCIATION; DRUG DOSE COMPARISON; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; FOLLOW UP; GLYCEMIC CONTROL; HEART ATRIUM FIBRILLATION; HUMAN; HYPERCOAGULABILITY; HYPERGLYCEMIA; HYPERTENSION; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; LOW DRUG DOSE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; RISK ASSESSMENT; RISK REDUCTION; STROKE; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

ANTIHYPERTENSIVE AGENTS; ANTILIPEMIC AGENTS; DIABETES MELLITUS, TYPE 2; FIBRINOLYTIC AGENTS; HUMANS; HYPOGLYCEMIC AGENTS; RISK; STROKE;

EID: 70349652585     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-009-5143-1     Document Type: Review

References (147)

1. Action to Control Cardiovascular Risk in Diabetes Study Group HC Gerstein ME Miller RP Byington DC Goff Jr JT Bigger JB Buse WC Cushman S Genuth F Ismail-Beigi RH Grimm Jr JL Probstfield DG Simons-Morton WT Friedewald 2008 Effects of intensive glucose lowering in type 2 diabetes N Engl J Med 358 2545 2559 10.1056/NEJMoa0802743 18539917 1:CAS:528:DC%2BD1cXnt1Wjs7s%3D (Pubitemid 351831356)
2. H Adachi Y Hirai M Tsuruta Y Fujiura T Imaizuml 2001 Is insulin resistance or diabetes mellitus associated with stroke? An 18-year follow-up study Diabetes Res Clin Pract 51 215 223 10.1016/S0168-8227(00)00236-9 11269894 1:CAS:528:DC%2BD3MXhvFCnsb8%3D (Pubitemid 32223916)
3. AI Adler IM Stratton HA Neil JS Yudkin DR Matthews CA Cull AD Wright RC Turner R Holman 2000 Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study BMJ 321 412 419 10.1136/bmj.321.7258.412 10938049 1:STN:280:DC%2BD3cvisFWnsw%3D%3D (Pubitemid 30609443)
4. ADVANCE Collaborative Group A Patel S MacMahon J Chalmers B Neal L Billot M Woodward M Marre M Cooper P Glasziou D Grobbee P Hamet S Harrap S Heller L Liu G Mancia CE Mogensen C Pan N Poulter A Rodgers B Williams S Bompoint BE de Galan R Joshi F Travert 2008 Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes N Engl J Med 358 2560 2572 10.1056/NEJMoa0802987 18539916 1:CAS:528:DC%2BD1cXnt1yht7s%3D (Pubitemid 351831357)
5. R Ajjan RF Storey PJ Grant 2008 Aspirin resistance and diabetes mellitus Diabetologia 51 385 390 10.1007/s00125-007-0898-3 18197397 1:STN:280: DC%2BD1c%2FosVyisQ%3D%3D
6. RA Ajjan PJ Grant 2008 The cardiovascular safety of rosiglitazone Expert Opin Drug Saf 7 367 376 10.1517/14740338.7.4.367 18613801 1:CAS:528: DC%2BD1cXos1Cgs78%3D
7. S Allemann P Diem M Egger ER Christ C Stettler 2006 Fibrates in the prevention of cardiovascular disease in patients with type 2 diabetes mellitus: meta-analysis of randomised controlled trials Curr Med Res Opin 22 617 623 10.1185/030079906X89865 16574044 1:CAS:528:DC%2BD28XjvV2htLc%3D
8. P Amarenco J Bogousslavsky A Callahan 3rd LB Goldstein M Hennerici AE Rudolph H Sillesen L Simunovic M Szarek KM Welch JA Zivin Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators 2006 High-dose atorvastatin after stroke or transient ischemic attack N Engl J Med 355 549 559 10.1056/NEJMoa061894 16899775 1:CAS:528:DC%2BD28XotVKgtb8%3D (Pubitemid 44202151)
9. Amarenco P, Goldstein LB, Callahan A 3rd, Sillesen H, Hennerici MG, O'Neill BJ, Rudolph AE, Simunovic L, Zivin JA, Welch KM; on behalf of the SPARCL Investigators (2008) Baseline blood pressure, low- and high-density lipoproteins, and triglycerides and the risk of vascular events in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Atherosclerosis [Epub ahead of print]
10. P Amarenco J Labreuche PJ Touboul 2008 High-density lipoprotein- cholesterol and risk of stroke and carotid atherosclerosis: a systematic review Atherosclerosis 196 489 496 10.1016/j.atherosclerosis.2007.07.033 17923134 1:CAS:528:DC%2BD1cXhsVCjsb8%3D (Pubitemid 351146660)
11. Antithrombotic Trialists' Collaboration 2002 Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients BMJ 324 71 86 10.1136/bmj.324. 7336.S71
12. A Arboix A Rivas L García-Eroles L de Marcos J Massons M Oliveres 2005 Cerebral infarction in diabetes: clinical pattern, stroke subtypes, and predictors of in-hospital mortality BMC Neurol 5 9 10.1186/1471-2377-5-9 15833108 (Pubitemid 41418218)
13. VG Athyros AA Papageorgiou AN Symeonidis TP Didangelos AN Pehlivanidis VI Bouloukos DP Mikhailidis GREACE Study Collaborative Group 2003 Early benefit from structured care with atorvastatin in patients with coronary heart disease and diabetes mellitus Angiology 54 679 690 10.1177/000331970305400607 14666956
14. HA Baalbaki DS Bell 2007 Insulin resistance and thrombogenesis: recent insights and therapeutic implications Endocr Pract 13 679 686 17954428
15. E Barrett-Connor KT Khaw 1988 Diabetes mellitus: an independent risk factor for stroke? Am J Epidemiol 128 116 123 3381820 1:STN:280: DyaL1c3ltVagtQ%3D%3D
16. JI Barzilay BR Davis J Bettencourt KL Margolis DC Goff Jr H Black G Habib A Ellsworth RW Force T Wiegmann JO Ciocon JN Basile ALLHAT Collaborative Research Group 2004 Cardiovascular outcomes using doxazosin vs. chlorthalidone for the treatment of hypertension in older adults with and without glucose disorders: a report from the ALLHAT study J Clin Hypertens (Greenwich) 6 116 125 10.1111/j.1524-6175.2004.03216.x 1:CAS:528:DC%2BD2cXisleru70%3D
17. GD Batty M Kivimäki G Davey Smith MG Marmot MJ Shipley 2008 Post-challenge blood glucose concentration and stroke mortality rates in non-diabetic men in London: 38-year follow-up of the original Whitehall prospective cohort study Diabetologia 51 1123 1126 10.1007/s00125-008-1005-0 18438641 1:STN:280:DC%2BD1czlt12gtg%3D%3D
18. J Belch A MacCuish I Campbell S Cobbe R Taylor R Prescott R Lee J Bancroft S MacEwan J Shepherd P Macfarlane A Morris R Jung C Kelly A Connacher N Peden A Jamieson D Matthews G Leese J McKnight I O'Brien C Semple J Petrie D Gordon S Pringle R MacWalter Prevention of Progression of Arterial Disease, Diabetes Study Group Diabetes Registry Group Royal College of Physicians Edinburgh 2008 The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease BMJ 337 a1840 18927173
19. T Berl LG Hunsicker JB Lewis MA Pfeffer JG Porush JL Rouleau PL Drury E Esmatjes D Hricik CR Parikh I Raz P Vanhille TB Wiegmann BM Wolfe F Locatelli SZ Goldhaber EJ Lewis Irbesartan Diabetic Nephropathy Trial, Collaborative Study Group 2003 Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy Ann Intern Med 138 542 549 12667024 1:CAS:528:DC%2BD3sXjtVejt7Y%3D
20. K Berthet BC Neal JP Chalmers SW MacMahon MG Bousser SA Colman M Woodward Perindopril Protection Against Recurrent Stroke Study Collaborative Group 2004 Reductions in the risks of recurrent stroke in patients with and without diabetes: the PROGRESS Trial Blood Press 13 7 13 10.1080/08037050410029605 15083634 (Pubitemid 38455840)
21. DJ Betteridge 2008 Lipid lowering in diabetes mellitus Curr Opin Lipidol 19 579 584 10.1097/MOL.0b013e328314b6b4 18957880 1:CAS:528:DC%2BD1cXht12gu7vN
22. DL Bhatt SP Marso AT Hirsch PA Ringleb W Hacke EJ Topol 2002 Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus Am J Cardiol 90 625 628 10.1016/S0002-9149(02)02567-5 12231089 (Pubitemid 35264538)
23. M Blanco MA Moro A Dávalos R Leira M Castellanos J Serena J Vivancos M Rodríguez-Yáñez I Lizasoain J Castillo 2005 Increased plasma levels of 15-deoxyDelta prostaglandin J2 are associated with good outcome in acute atherothrombotic ischemic stroke Stroke 36 1189 1194 10.1161/01.STR.0000166054.55993.e5 15879329 1:CAS:528:DC%2BD2MXksVWrtLg%3D (Pubitemid 40798737)
24. B Boden-Albala S Cammack J Chong C Wang C Wright T Rundek MS Elkind MC Paik RL Sacco 2008 Diabetes, fasting glucose levels, and risk of ischemic stroke and vascular events: findings from the Northern Manhattan Study (NOMAS) Diabetes Care 31 6 1132 1137 10.2337/dc07-0797 18339972
25. ML Bots PC Elwood Y Nikitin JT Salonen A Freire de Concalves D Inzitari J Sivenius V Benetou J Tuomilehto PJ Koudstaal DE Grobbee 2002 Total and HDL cholesterol and risk of stroke. EUROSTROKE: a collaborative study among research centres in Europe J Epidemiol Community Health 56 Suppl 1 i19 i24 10.1136/jech.56.suppl-1.i19 11815640
26. TS Bowman HD Sesso J Ma T Kurth CS Kase MJ Stampfer JM Gaziano 2003 Cholesterol and the risk of ischemic stroke Stroke 34 2930 2934 10.1161/01.STR.0000102171.91292.DC 14615618 1:CAS:528:DC%2BD3sXpt1Krurs%3D (Pubitemid 37517771)
27. G Brohall A Odén B Fagerberg 2006 Carotid artery intima-media thickness in patients with Type 2 diabetes mellitus and impaired glucose tolerance: a systematic review Diabet Med 23 609 616 10.1111/j.1464-5491.2005. 01725.x 16759301 1:STN:280:DC%2BD28zks1Cktw%3D%3D (Pubitemid 43830060)
28. CM Brown H Marthol U Zikeli D Ziegler MJ Hilz 2008 A simple deep breathing test reveals altered cerebral autoregulation in type 2 diabetic patients Diabetologia 51 756 761 10.1007/s00125-008-0958-3 18309474 1:STN:280:DC%2BD1c3jtFyhsQ%3D%3D
29. SE Capes D Hunt K Malmberg P Pathak HC Gerstein 2001 Stress hyperglycemia and prognosis of stroke in nondiabetic and diabetic patients: a systematic overview Stroke 32 2426 2432 10.1161/hs1001.096194 11588337 1:STN:280: DC%2BD3MrktFGrsQ%3D%3D
30. ME Carr 2001 Diabetes mellitus: a hypercoagulable state J Diabetes Complicat 15 44 54 10.1016/S1056-8727(00)00132-X 11259926 1:STN:280: DC%2BD3M7mtFaruw%3D%3D (Pubitemid 32203891)
31. A Carter MO Murphy NJ Turner AT Halka J Ghosh F Serracino-Inglott MG Walker F Syed 2007 Initimal neovascularisation is a prominent feature of atherosclerotic plaques in diabetic patients with critical limb ischaemia Eur J Vasc Endovasc Surg 33 319 324 10.1016/j.ejvs.2006.10.021 17164094 1:STN:280:DC%2BD2s%2FptVaisA%3D%3D (Pubitemid 46196394)
32. Cholesterol Treatment Trialists' (CTT) Collaborators PM Kearney L Blackwell R Collins A Keech J Simes R Peto J Armitage C Baigent 2008 Efficacy of cholesterol-lowering therapy in 18, 686 people with diabetes in 14 randomised trials of statins: a meta-analysis Lancet 371 117 125 10.1016/S0140-6736(08) 60104-X 18191683 1:STN:280:DC%2BD1c%2FjvVWmsg%3D%3D
33. F Cipollone A Iezzi M Fazia M Zucchelli B Pini C Cuccurullo D De Cesare G De Blasis R Muraro R Bei F Chiarelli AM Schmidt F Cuccurullo A Mezzetti 2003 The receptor RAGE as a progression factor amplifying arachidonate-dependent inflammatory and proteolytic response in human atherosclerotic plaques: role of glycemic control Circulation 108 1070 1077 10.1161/01.CIR.0000086014.80477.0D 12912808 1:CAS:528:DC%2BD3sXms1altbs%3D (Pubitemid 37071516)
34. HM Colhoun DJ Betteridge PN Durrington GA Hitman HA Neil SJ Livingstone MJ Thomason MI Mackness V Charlton-Menys JH Fuller CARDS investigators 2004 Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomized placebo-controlled trial Lancet 364 685 696 10.1016/S0140-6736(04) 16895-5 15325833 1:CAS:528:DC%2BD2cXmvFWltrY%3D (Pubitemid 39140624)
35. M Collino M Aragno R Mastrocola M Gallicchio AC Rosa C Dianzani O Danni C Thiemermann R Fantozzi 2006 Modulation of the oxidative stress and inflammatory response by PPAR-gamma agonists in the hippocampus of rats exposed to cerebral ischemia/reperfusion Eur J Pharmacol 530 70 80 10.1016/j.ejphar.2005.11.049 16386242 1:CAS:528:DC%2BD28XhsFeqsw%3D%3D (Pubitemid 43037126)
36. JD Curb SL Pressel JA Cutler PJ Savage WB Applegate H Black G Camel BR Davis PH Frost N Gonzalez G Guthrie A Oberman GH Rutan J Stamler 1996 Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group JAMA 276 1886 1892 10.1001/jama.276.23.1886 8968014 1:CAS:528:DyaK2sXjt1KrsQ%3D%3D (Pubitemid 26419185)
37. P Dandona A Chaudhuri H Ghanim P Mohanty 2007 Proinflammatory effects of glucose and anti-inflammatory effect of insulin: relevance to cardiovascular disease Am J Cardiol 99 15B 26B 10.1016/j.amjcard.2006.11.003 17307055 1:CAS:528:DC%2BD2sXjsVKmsrc%3D (Pubitemid 46239948)
38. M Davidson PM Meyer S Haffner S Feinstein R D'Agostino Sr GT Kondos A Perez Z Chen T Mazzone 2008 Increased high-density lipoprotein cholesterol predicts the pioglitazone-mediated reduction of carotid intima-media thickness progression in patients with type 2 diabetes mellitus Circulation 117 2123 2130 10.1161/CIRCULATIONAHA.107.746610 18413496 1:CAS:528:DC%2BD1cXks1Gjsb4%3D (Pubitemid 351572171)
39. TM Davis H Millns IM Stratton RR Holman RC Turner 1999 Risk factors for stroke in type 2 diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS) 29 Arch Intern Med 159 1097 1103 10.1001/archinte.159.10.1097 10335687 1:STN:280:DyaK1M3ms1Oiug%3D%3D (Pubitemid 29230862)
40. G de Jong L van Raak F Kessels J Lodder 2003 Stroke subtype and mortality. A follow-up study in 998 patients with a first cerebral infarct J Clin Epidemiol 56 262 268 10.1016/S0895-4356(02)00572-3 12725881 (Pubitemid 36513488)
41. PJ Delahoy DJ Magliano K Webb M Grobler D Liew 2009 The relationship between reduction in low-density lipoprotein cholesterol by statins and reduction in risk of cardiovascular outcomes: an updated meta-analysis Clin Ther 31 236 244 10.1016/j.clinthera.2009.02.017 19302897 1:CAS:528: DC%2BD1MXkvVCru70%3D
42. JA Dormandy B Charbonnel DJ Eckland E Erdmann M Massi-Benedetti IK Moules AM Skene MH Tan PJ Lefèbvre GD Murray E Standl RG Wilcox L Wilhelmsen J Betteridge K Birkeland A Golay RJ Heine L Korányi M Laakso M Mokán A Norkus V Pirags T Podar A Scheen W Scherbaum G Schernthaner O Schmitz J Skrha U Smith J Taton PROactive investigators 2005 Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial Lancet 366 1279 1289 10.1016/S0140-6736(05)67528-9 16214598 1:CAS:528:DC%2BD2MXhtVOlu7fO (Pubitemid 41416583)
43. S Ebrahim J Sung Y-M Song R Ferrer DA Lawlor G Davey Smith 2006 Serum cholesterol, haemorrhagic stroke, ischaemic stroke, and myocardial infarction: Korean national health system prospective cohort study BMJ 333 22 10.1136/bmj.38855.610324.80 16757495 (Pubitemid 44406841)
44. E Erdmann JA Dormandy B Charbonnel M Massi-Benedetti IK Moules AM Skene PROactive Investigators 2007 The effect of pioglitazone on recurrent myocardial infarction in 2, 445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) study J Am Coll Cardiol 49 1772 1780 10.1016/j.jacc.2006.12.048 17466227 1:CAS:528:DC%2BD2sXkslCgsLs%3D (Pubitemid 46629127)
45. RO Estacio BW Jeffers WR Hiatt SL Biggerstaff N Gifford RW Schrier 1998 The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension N Engl J Med 338 645 652 10.1056/NEJM199803053381003 9486993 1:CAS:528:DyaK1cXhvVylu78%3D (Pubitemid 28108434)
46. P Gaede H Lund-Andersen HH Parving O Pedersen 2008 Effect of a multifactorial intervention on mortality in type 2 diabetes N Engl J Med 358 580 591 10.1056/NEJMoa0706245 18256393 1:CAS:528:DC%2BD1cXhs1entLc%3D (Pubitemid 351214285)
47. P Gæde O Pedersen 2004 Intensive integrated therapy of type 2 diabetes: implications for long-term prognosis Diabetes 53 Suppl 3 S39 S47 10.2337/diabetes.53.suppl-3.S39 15561920 (Pubitemid 39564521)
48. R Garg A Chaudhuri F Munschauer P Dandona 2006 Hyperglycemia, insulin, and acute ischemic stroke: a mechanistic justification for a trial of insulin infusion therapy Stroke 37 267 273 10.1161/01.STR.0000195175.29487.30 16306459 1:CAS:528:DC%2BD2MXhtlagsb7K (Pubitemid 43732090)
49. NT Gentile VR Vaidyula U Kanamalla M DeAngelis J Gaughan AK Rao 2007 Factor VIIa and tissue factor procoagulant activity in diabetes mellitus after acute ischemic stroke: impact of hyperglycemia Thromb Haemost 98 1007 1013 18000605 1:CAS:528:DC%2BD2sXhsVWrsbnM
50. RB Goldberg MJ Mellies FM Sacks LA Moyé BV Howard WJ Howard BR Davis TG Cole MA Pfeffer E Braunwald 1998 Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels. Subgroup analyses in the cholesterol and recurrent events (CARE) trial Circulation 98 2513 2519 9843456 1:CAS:528:DyaK1MXlvVei (Pubitemid 29001188)
51. PJ Grant 2007 Diabetes mellitus as a prothrombotic condition J Intern Med 262 157 172 10.1111/j.1365-2796.2007.01824.x 17645584 1:CAS:528: DC%2BD2sXhtVens7nO (Pubitemid 47090159)
52. CS Gray AJ Hildreth PA Sandercock JE O'Connell DE Johnston NE Cartlidge JM Bamford OF James KG Alberti GIST Trialists Collaboration 2007 Glucose-potassium-insulin infusions in the management of post-stroke hyperglycaemia: the UK Glucose Insulin in Stroke Trial (GIST-UK) Lancet Neurol 6 397 406 10.1016/S1474-4422(07)70080-7 17434094 1:CAS:528:DC%2BD2sXmtVyrsLc%3D (Pubitemid 46551852)
53. L Hansson T Hedner P Lund-Johansen SE Kjeldsen LH Lindholm JO Syvertsen J Lanke U de Faire B Dahlöf BE Karlberg 2000 Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study Lancet 356 359 365 10.1016/S0140-6736(00)02526-5 10972367 1:CAS:528: DC%2BD3cXls1Clu7Y%3D
54. L Hansson A Zanchetti SG Carruthers B Dahlöf D Elmfeldt S Julius J Ménard KH Rahn H Wedel S Westerling 1998 Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group Lancet 351 1755 1762 10.1016/S0140-6736(98)04311-6 9635947 1:CAS:528:DyaK1cXksV2qtrY%3D (Pubitemid 28269185)
55. P Harmsen G Lappas A Rosengren L Wilhelmsen 2006 Long-term risk factors for stroke: twenty-eight years of follow-up of 7457 middle-aged men in Goteborg, Sweden Stroke 37 1663 1667 10.1161/01.STR.0000226604.10877.fc 16728686 (Pubitemid 44297709)
56. CL Hart DJ Hole GD Smith 1999 Risk factors and 20-year stroke mortality in men and women in the Renfrew/Paisley study in Scotland Stroke 30 1999 2007 10512898 1:STN:280:DyaK1Mvktl2qsA%3D%3D
57. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators 2000 Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy Lancet 355 253 259 10.1016/S0140-6736(99)12323-7 (Pubitemid 30068516)
58. Heart Protection Study Collaborative Group 2003 MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial Lancet 361 2005 2016 10.1016/S0140-6736(03) 13636-7 (Pubitemid 36695042)
59. JE Ho F Paultre L Mosca Women's Pooling Project 2003 Is diabetes mellitus a cardiovascular disease risk equivalent for fatal stroke in women? Data from the Women's Pooling Project Stroke 34 2812 2816 10.1161/01.STR.0000102901.41780. 5C 14657546 (Pubitemid 37517747)
60. I Holme AH Aastveit N Hammar I Jungner G Walldius 2009 Relationships between lipoprotein components and risk of ischaemic and haemorrhagic stroke in the Apolipoprotein MOrtality RISk study (AMORIS) J Intern Med 265 275 287 10.1111/j.1365-2796.2008.02016.x 19019184 1:CAS:528:DC%2BD1MXjt1CmsbY%3D
61. G Hu P Jousilahti C Sarti R Antikainen J Tuomilehto 2006 The effect of diabetes and stroke at baseline and during follow-up on stroke mortality Diabetologia 49 2309 2316 10.1007/s00125-006-0378-1 16896934 1:STN:280:DC%2BD28rivFOqsw%3D%3D (Pubitemid 44359091)
62. G Hu C Sarti P Jousilahti M Peltonen Q Qiao R Antikainen J Tuomilehto 2005 The impact of history of hypertension and type 2 diabetes at baseline on the incidence of stroke and stroke mortality Stroke 36 2538 2543 10.1161/01.STR.0000190894.30964.75 16282538
63. L Hui DS Pei QG Zhang QH Guan GY Zhang 2005 The neuroprotection of insulin on ischemic brain injury in rat hippocampus through negative regulation of JNK signaling pathway by PI3K/Akt activation Brain Res 1052 1 9 10.1016/j.brainres.2005.05.043 16018989 1:CAS:528:DC%2BD2MXnslyisbo%3D (Pubitemid 41116281)
64. IDF Clinical Guidelines Task Force (2005) Global guideline for type 2 diabetes. International Diabetes Federation, Brussels
65. M Janghorbani FB Hu WC Willett TY Li JE Manson G Logroscino KM Rexrode 2007 Prospective study of type 1 and type 2 diabetes and risk of stroke subtypes: the Nurses' Health Study Diabetes Care 30 1730 1735 10.2337/dc06-2363 17389335 (Pubitemid 47036344)
66. K Kario J Ishikawa S Hoshide Y Matsui M Morinari K Eguchi S Ishikawa K Shimada 2005 Diabetic brain damage in hypertension: role of renin-angiotensin system Hypertension 45 887 893 10.1161/01.HYP.0000163460.07639.3f 15824198 1:CAS:528:DC%2BD2MXjtlymu7c%3D (Pubitemid 40628933)
67. A Keech D Colquhoun J Best A Kirby RJ Simes D Hunt W Hague E Beller M Arulchelvam J Baker A Tonkin LIPID Study Group 2003 Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trial Diabetes Care 26 2713 2721 10.2337/diacare.26.10.2713 14514569 1:CAS:528:DC%2BD3sXosF2js74%3D (Pubitemid 37205536)
68. A Keech D Colquhoun J Best A Kirby RJ Simes D Hunt W Hague E Beller M Arulchelvam J Baker A Tonkin LIPID Study Group 2002 Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT) Arch Intern Med 162 2597 2604 10.1001/archinte.162.22.2597 (Pubitemid 35453499)
69. WN Kernan SE Inzucchi CM Viscoli LM Brass DM Bravata RI Horwitz 2002 Insulin resistance and risk for stroke Neurology 59 809 815 12349850 1:CAS:528:DC%2BD38XntVynsLk%3D
70. BM Kissela J Khoury D Kleindorfer D Woo A Schneider K Alwell R Miller I Ewing CJ Moomaw JP Szaflarski J Gebel R Shukla JP Broderick 2005 Epidemiology of ischemic stroke in patients with diabetes: the greater Cincinnati/Northern Kentucky Stroke Study Diabetes Care 28 355 359 10.2337/diacare.28.2.355 15677792 (Pubitemid 40170939)
71. RH Knopp M d'Emden JG Smilde SJ Pocock 2006 Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN) Diabetes Care 29 1478 1485 10.2337/dc05-2415 16801565 1:CAS:528:DC%2BD28XnsVahtbk%3D (Pubitemid 44127567)
72. N Koren-Morag D Tanne E Graff U Goldbourt 2002 Low- and high-density lipoprotein cholesterol and ischemic cerebrovascular disease: the bezafibrate infarction prevention registry Arch Intern Med 162 993 999 10.1001/archinte.162. 9.993 11996608 1:CAS:528:DC%2BD38Xkt12rsb0%3D
73. K Lakshminarayan DC Anderson CA Herzog AI Qureshi 2008 Clinical epidemiology of atrial fibrillation and related cerebrovascular events in the United States Neurologist 14 143 150 10.1097/NRL.0b013e31815cffae 18469671 (Pubitemid 351671254)
74. J Lee M Reding 2007 Effects of thiazolidinediones on stroke recovery: a case-matched controlled study Neurochem Res 32 635 638 10.1007/s11064-006-9138-3 16960755 1:CAS:528:DC%2BD2sXjtlynurw%3D (Pubitemid 46481294)
75. S Lehto T Rönnemaa K Pyörälä M Laakso 1996 Predictors of stroke in middle-aged patients with non-insulin-dependent diabetes Stroke 27 63 68 8553405 1:STN:280:DyaK287js1antQ%3D%3D
76. AM Lincoff K Wolski SJ Nicholls SE Nissen 2007 Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials JAMA 298 1180 1188 10.1001/jama.298.10.1180 17848652 1:CAS:528:DC%2BD2sXhtVGmtL3J (Pubitemid 47403104)
77. LH Lindholm L Hansson T Ekbom B Dahlöf J Lanke E Linjer B Scherstén PO Wester T Hedner U de Faire 2000 Comparison of antihypertensive treatments in preventing cardiovascular events in elderly diabetic patients: results from the Swedish Trial in Old Patients with Hypertension-2. STOP Hypertension-2 Study Group J Hypertens 18 1671 1675 10.1097/00004872-200018110-00020 11081782 1:CAS:528:DC%2BD3cXosFOkur0%3D
78. LH Lindholm H Ibsen K Borch-Johnsen MH Olsen K Wachtell B Dahlöf RB Devereux G Beevers U de Faire F Fyhrquist S Julius SE Kjeldsen K Kristianson O Lederballe-Pedersen MS Nieminen P Omvik S Oparil H Wedel P Aurup JM Edelman S Snapinn For the LIFE study group 2002 Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study J Hypertens 20 1879 1886 10.1097/00004872-200209000-00035 12195132 1:CAS:528:DC%2BD38XntlOmt7g%3D (Pubitemid 35041980)
79. Y Luo W Yin AP Signore F Zhang Z Hong S Wang SH Graham J Chen 2006 Neuroprotection against focal ischemic brain injury by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone J Neurochem 97 435 448 10.1111/j.1471-4159.2006.03758.x 16539667 1:CAS:528:DC%2BD28XksVykt7c%3D
80. G Mancia M Brown A Castaigne P de Leeuw CR Palmer T Rosenthal G Wagener LM Ruilope INSIGHT 2003 Outcomes with nifedipine GITS or Co-amilozide in hypertensive diabetics and nondiabetics in Intervention as a Goal in Hypertension (INSIGHT) Hypertension 41 431 436 10.1161/01.HYP.0000057420.27692. AD 12623939 1:CAS:528:DC%2BD3sXhsV2ksrs%3D (Pubitemid 36314612)
81. BN Mankovsky D Ziegler 2004 Stroke in patients with diabetes mellitus Diabetes Metab Res Rev 20 268 287 10.1002/dmrr.490 15250030 (Pubitemid 39077478)
82. M Marre M Lievre G Chatellier JF Mann P Passa J Ménard DIABHYCAR Study Investigators 2004 Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study) BMJ 328 495 10.1136/bmj.37970.629537.0D 14960504 1:CAS:528: DC%2BD2cXjtVansbo%3D
83. M Mazighi J Labreuche F Gongora-Rivera C Duyckaerts JJ Hauw P Amarenco 2008 Autopsy prevalence of intracranial atherosclerosis in patients with fatal stroke Stroke 39 1142 1147 10.1161/STROKEAHA.107.496513 18309170
84. T Mazzone PM Meyer SB Feinstein MH Davidson GT Kondos RB D'Agostino Sr A Perez JC Provost SM Haffner 2006 Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial JAMA 296 2572 2581 10.1001/jama.296.21.joc60158 17101640 1:CAS:528:DC%2BD28Xht12lsbbM (Pubitemid 44903861)
85. SE Megherbi C Milan D Minier G Couvreur GV Osseby K Tilling A Di Carlo D Inzitari CD Wolfe T Moreau M Giroud European BIOMED Study of Stroke Care Group 2003 Association between diabetes and stroke subtype on survival and functional outcome 3 months after stroke: data from the European BIOMED Stroke Project Stroke 34 688 694 10.1161/01.STR.0000057975.15221.40 12624292 (Pubitemid 36307394)
86. PR Moreno AM Murcia IF Palacios MN Leon VH Bernardi V Fuster JT Fallon 2000 Coronary composition and macrophage infiltration in atherectomy specimens from patients with diabetes mellitus Circulation 102 2180 2184 11056089 1:STN:280:DC%2BD3crgslWqsw%3D%3D
87. PK Myint S Sinha NJ Wareham SA Bingham RN Luben AA Welch KT Khaw 2007 Glycated hemoglobin and risk of stroke in people without known diabetes in the European Prospective Investigation into Cancer (EPIC)-Norfolk prospective population study: a threshold relationship? Stroke 38 271 275 10.1161/01.STR.0000254549.75763.5f 17204684 1:CAS:528:DC%2BD2sXotVSmsg%3D%3D (Pubitemid 46184293)
88. T Nakamura E Yamamoto K Kataoka T Yamashita Y Tokutomi YF Dong S Matsuba H Ogawa S Kim-Mitsuyama 2007 Pioglitazone exerts protective effects against stroke in stroke-prone spontaneously hypertensive rats, independently of blood pressure Stroke 38 3016 3022 10.1161/STROKEAHA.107.486522 17885259 1:CAS:528:DC%2BD2sXhtF2itbnJ (Pubitemid 350041562)
89. A Natali E Toschi S Baldeweg D Ciociaro S Favilla L Saccà E Ferrannini 2006 Clustering of insulin resistance with vascular dysfunction and low-grade inflammation in type 2 diabetes Diabetes 55 1133 1140 10.2337/diabetes.55.04.06.db05-1076 16567539 1:CAS:528:DC%2BD28XjsVGmur4%3D (Pubitemid 44100192)
90. J Nigro N Osman AM Dart PJ Little 2006 Insulin resistance and atherosclerosis Endocr Rev 27 242 259 10.1210/er.2005-0007 16492903 1:CAS:528:DC%2BD28XlsFamsL0%3D
91. L Niskanen T Hedner L Hansson J Lanke A Niklason CAPPP Study Group 2001 Reduced cardiovascular morbidity and mortality in hypertensive diabetic patients on first-line therapy with an ACE inhibitor compared with a diuretic/beta-blocker-based treatment regimen: a subanalysis of the Captopril Prevention Project Diabetes Care 24 2091 2096 10.2337/diacare.24.12.2091 11723089 1:CAS:528:DC%2BD3MXpt1Kis7c%3D
92. SE Nissen SJ Nicholls K Wolski R Nesto S Kupfer A Perez H Jure R De Larochellière CS Staniloae K Mavromatis J Saw B Hu AM Lincoff PERISCOPE Tuzcu EM Investigators 2008 Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes, The PERISCOPE randomized controlled trial JAMA 299 1561 1573 10.1001/jama.299.13. 1561 18378631 1:CAS:528:DC%2BD1cXktlSqtbg%3D
93. H Ogawa M Nakayama T Morimoto S Uemura M Kanauchi N Doi H Jinnouchi S Sugiyama Y Saito Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) Trial Investigators 2008 Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial JAMA 300 2134 2141 10.1001/jama.2008.623 18997198 1:CAS:528:DC%2BD1cXhtlOrtLnM
94. M Paciaroni M Hennerici G Agnelli J Bogousslavsky 2007 Statins and stroke prevention Cerebrovasc Dis 24 170 182 10.1159/000104474 17596685 1:CAS:528:DC%2BD2sXpsVaru7c%3D (Pubitemid 47295581)
95. A Patel M Woodward DJ Campbell DR Sullivan S Colman J Chalmers B Neal S MacMahon 2005 Plasma lipids predict myocardial infarction, but not stroke, in patients with established cerebrovascular disease Eur Heart J 26 1910 1915 10.1093/eurheartj/ehi407 16006443 1:CAS:528:DC%2BD2MXhtFGqsrfL (Pubitemid 41253305)
96. A Patel ADVANCE Collaborative Group S MacMahon J Chalmers B Neal M Woodward L Billot S Harrap N Poulter M Marre M Cooper P Glasziou DE Grobbee P Hamet S Heller LS Liu G Mancia CE Mogensen CY Pan A Rodgers B Williams 2007 Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial Lancet 370 340 829 10.1016/S0140-6736(07)61303-8 (Pubitemid 47362321)
97. PROGRESS Collaborative Group 2001 Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack Lancet 358 1033 1041 10.1016/S0140-6736(01)06178-5 (Pubitemid 32925123)
98. Prospective Studies Collaboration S Lewington G Whitlock R Clarke P Sherliker J Emberson J Halsey N Qizilbash R Peto R Collins 2007 Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths Lancet 370 1829 1839 10.1016/S0140-6736(07)61778-4 18061058 (Pubitemid 350180032)
99. PA Ringleb 2008 Guidelines for management of ischaemic stroke and transient ischaemic attack 2008 Cerebrovasc Dis 25 457 507 10.1159/000131083 (Pubitemid 351754643)
100. NN Rizk J Rafols JC Dunbar 2006 Cerebral ischemia-induced apoptosis and necrosis in normal and diabetic rats: effects of insulin and C-peptide Brain Res 1096 204 212 10.1016/j.brainres.2006.04.060 16729987 1:CAS:528: DC%2BD28Xmt1yisrk%3D (Pubitemid 43928921)
101. M Rizzo E Corrado G Coppola I Muratori G Novo S Novo 2008 Prediction of cardio- and cerebro-vascular events in patients with subclinical carotid atherosclerosis and low HDL-cholesterol Atherosclerosis 200 389 395 10.1016/j.atherosclerosis.2007.12.020 18258237 1:CAS:528:DC%2BD1cXhtFylt7%2FL
102. D Roccatagliata F Avanzini L Monesi V Caimi D Lauri P Longoni R Marchioli M Tombesi G Tognoni MC Roncaglioni Collaborative Group Risk Prevention Study 2006 Is global cardiovascular risk considered in current practice? Treatment and control of hypertension, hyperlipidemia, and diabetes according to patients' risk level Vasc Health Risk Manag 2 507 514 10.2147/vhrm.2006.2.4.507 17323606 (Pubitemid 46231281)
103. N Rodondi T Peng AJ Karter DC Bauer E Vittinghoff S Tang D Pettitt EA Kerr JV Selby 2006 Therapy modifications in response to poorly controlled hypertension, dyslipidemia, and diabetes mellitus Ann Intern Med 144 475 484 16585661
104. J Rohr S Kittner B Feeser JR Hebel MG Whyte A Weinstein N Kanarak D Buchholz C Earley C Johnson R Macko T Price M Sloan B Stern R Wityk M Wozniak R Sherwin 1996 Traditional risk factors and ischemic stroke in young adults: the Baltimore-Washington Cooperative Young Stroke Study Arch Neurol 53 603 607 8929167 1:STN:280:DyaK283ntFegsA%3D%3D
105. C Romera O Hurtado J Mallolas MP Pereira JR Morales A Romera J Serena J Vivancos F Nombela P Lorenzo I Lizasoain MA Moro 2007 Ischemic preconditioning reveals that GLT1/EAAT2 glutamate transporter is a novel PPARgamma target gene involved in neuroprotection J Cereb Blood Flow Metab 27 1327 1338 10.1038/sj.jcbfm.9600438 17213861 1:CAS:528:DC%2BD2sXnvFCqsLs%3D (Pubitemid 46985349)
106. M Rosvall L Janzon G Berglund G Engström B Hedblad 2005 Incidence of stroke is related to carotid IMT even in the absence of plaque Atherosclerosis 179 325 331 10.1016/j.atherosclerosis.2004.10.015 15777549 1:CAS:528: DC%2BD2MXitlCju7w%3D (Pubitemid 40364627)
107. HB Rubins SJ Robins D Collins DB Nelson MB Elam EJ Schaefer FH Faas JW Anderson 2002 Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT) Arch Intern Med 162 2597 2604 10.1001/archinte.162. 22.2597 12456232 1:CAS:528:DC%2BD38Xpslens70%3D (Pubitemid 35453499)
108. L Rydén E Standl M Bartnik G Van den Berghe J Betteridge MJ de Boer F Cosentino B Jönsson M Laakso K Malmberg S Priori J Ostergren J Tuomilehto I Thrainsdottir I Vanhorebeek M Stramba-Badiale P Lindgren Q Qiao SG Priori JJ Blanc A Budaj J Camm V Dean J Deckers K Dickstein J Lekakis K McGregor M Metra J Morais A Osterspey J Tamargo JL Zamorano JW Deckers M Bertrand B Charbonnel E Erdmann E Ferrannini A Flyvbjerg H Gohlke JR Juanatey I Graham PF Monteiro K Parhofer K Pyörälä I Raz G Schernthaner M Volpe D Wood Task Force on Diabetes, Cardiovascular Diseases of the European Society of Cardiology (ESC) European Association for the Study of Diabetes (EASD) 2007 Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary, The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD) Eur Heart J 28 88 136 10.1093/eurheartj/ehm124 17220161 (Pubitemid 47355991)
109. M Sacco F Pellegrini MC Roncaglioni F Avanzini G Tognoni A Nicolucci PPP Collaborative Group 2003 Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial Diabetes Care 26 3264 3272 10.2337/diacare.26.12.3264 14633812 1:CAS:528:DC%2BD3sXpvF2ks7Y%3D (Pubitemid 37466885)
110. JH Scarpello 2003 Improving survival with metformin: the evidence base today Diabetes Metab 29 4 Pt 2 S36 S43
111. JA Schmittdiel CS Uratsu AJ Karter M Heisler U Subramanian CM Mangione JV Selby 2008 Why don't diabetes patients achieve recommended risk factor targets? Poor adherence versus lack of treatment intensification J Gen Intern Med 23 588 594 10.1007/s11606-008-0554-8 18317847
112. RW Schrier RO Estacio A Esler P Mehler 2002 Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes Kidney Int 61 1086 1097 10.1046/j.1523-1755.2002.00213.x 11849464 (Pubitemid 34175478)
113. E Selvin J Coresh E Shahar L Zhang M Steffes AR Sharrett 2005 Glycaemia (haemoglobin A1c) and incident ischaemic stroke: the Atherosclerosis Risk in Communities (ARIC) Study Lancet Neurol 4 821 826 10.1016/S1474-4422(05)70227-1 16297840 1:CAS:528:DC%2BD2MXhtlWmtrjJ (Pubitemid 41619437)
114. PS Sever NR Poulter B Dahlöf H Wedel R Collins G Beevers M Caulfield SE Kjeldsen A Kristinsson GT McInnes J Mehlsen M Nieminen E O'Brien J Ostergren 2005 Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial-lipid-lowering arm (ASCOT-LLA) Diabetes Care 28 1151 1157 10.2337/diacare.28.5.1151 15855581 1:CAS:528:DC%2BD2MXksF2gsrw%3D (Pubitemid 40616627)
115. E Shahar LE Chambless WD Rosamond LL Boland CM Ballantyne PG McGovern AR Sharrett Atherosclerosis Risk in Communities Study 2003 Plasma lipid profile and incident ischemic stroke: the Atherosclerosis Risk in Communities (ARIC) study Stroke 34 623 631 10.1161/01.STR.0000057812.51734.FF 12624282 (Pubitemid 36307382)
116. J Shepherd P Barter R Carmena P Deedwania JC Fruchart S Haffner J Hsia A Breazna J LaRosa S Grundy D Waters 2006 Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study Diabetes Care 29 1220 1226 10.2337/dc05-2465 16731999 1:CAS:528:DC%2BD28XmtFKmu7c%3D (Pubitemid 44125913)
117. Y Shinohara F Gotoh H Tohgi S Hirai A Terashi Y Fukuuchi E Otomo E Itoh T Matsuda T Sawada T Yamaguchi K Nishimaru Y Ohashi 2008 Antiplatelet cilostazol is beneficial in diabetic and/or hypertensive ischemic stroke patients, Subgroup analysis of the cilostazol stroke prevention study Cerebrovasc Dis 26 63 70 10.1159/000135654 18511873 1:CAS:528:DC%2BD1cXnvFCis7w%3D (Pubitemid 351931422)
118. DE Singer GW Albers JE Dalen AS Go JL Halperin WJ Manning 2004 Antithrombotic therapy in atrial fibrillation: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest 126 Suppl 3 429S 456S 10.1378/chest.126.3-suppl.429S 15383480 1:CAS:528:DC%2BD2cXptV2msbg%3D (Pubitemid 39302603)
119. PJ Smith M Hurlen M Abdelnoor H Arnesen 2008 Less benefit from warfarin in diabetics after myocardial infarction? Cardiology 111 161 166 10.1159/000121598 18434719 1:CAS:528:DC%2BD1cXhtFKhtbfO
120. C Stettler S Allemann P Jüni CA Cull RR Holman M Egger S Krähenbühl P Diem 2006 Glycemic control and macrovascular disease in types 1 and 2 diabetes mellitus: meta-analysis of randomized trials Am Heart J 152 27 38 10.1016/j.ahj.2005.09.015 16824829 1:CAS:528:DC%2BD28Xms1Gkt7k%3D (Pubitemid 43974725)
121. RJ Stevens RL Coleman AI Adler IM Stratton DR Matthews RR Holman 2004 Risk factors for myocardial infarction case fatality and stroke case fatality in type 2 diabetes: UKPDS 66 Diabetes Care 27 201 207 10.2337/diacare.27.1.201 14693990 (Pubitemid 38196733)
122. IM Stratton AI Adler HA Neil DR Matthews SE Manley CA Cull D Hadden RC Turner RR Holman 2000 Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study BMJ 321 405 412 10.1136/bmj.321.7258.405 10938048 1:STN:280:DC%2BD3cvisFWnsg%3D%3D
123. IM Stratton CA Cull AI Adler DR Matthews HA Neil RR Holman 2006 Additive effects of glycaemia and blood pressure exposure on risk of complications in type 2 diabetes: a prospective observational study (UKPDS 75) Diabetologia 49 1761 1769 10.1007/s00125-006-0297-1 16736131 1:STN:280:DC%2BD28vgslyhsg%3D%3D (Pubitemid 44025030)
124. Stroke Risk Working Group in Atrial Fibrillation 2007 Independent predictors of stroke in patients with atrial fibrillation: a systematic review Neurology 69 546 554 10.1212/01.wnl.0000267275.68538.8d (Pubitemid 47357261)
125. D Tanne N Koren-Morag E Graff U Goldbourt 2001 Blood lipids and first-ever ischemic stroke/transient ischemic attack in the Bezafibrate Infarction Prevention (BIP) Registry: high triglycerides constitute an independent risk factor Circulation 104 2892 2897 10.1161/hc4901.100384 11739302 1:CAS:528:DC%2BD38XjvVKisQ%3D%3D
126. P Tatti M Pahor RP Byington P Di Mauro R Guarisco G Strollo F Strollo 1998 Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM Diabetes Care 21 597 603 10.2337/diacare.21.4.597 9571349 1:STN:280:DyaK1c3jt1ynsg%3D%3D (Pubitemid 28172941)
127. DL Tirschwell NL Smith SR Heckbert RN Lemaitre WT Longstreth Jr BM Psaty 2004 Association of cholesterol with stroke risk varies in stroke subtypes and patient subgroups Neurology 63 1868 1875 15557504 1:CAS:528:DC%2BD2cXpt1eiu7o%3D
128. J Tuomilehto D Rastenyte P Jousilahti C Sarti E Vartiainen 1996 Diabetes mellitus as a risk factor for death from stroke. Prospective study of the middle-aged Finnish population Stroke 27 210 215 8571411 1:STN:280: DyaK287msFChug%3D%3D (Pubitemid 26044488)
129. K Tureyen R Kapadia KK Bowen I Satriotomo J Liang DL Feinstein R Vemuganti 2007 Peroxisome proliferator-activated receptor-gamma agonists induce neuroprotection following transient focal ischemia in normotensive, normoglycemic as well as hypertensive and type-2 diabetic rodents J Neurochem 101 41 56 10.1111/j.1471-4159.2006.04376.x 17394460 1:CAS:528: DC%2BD2sXksFSqsLk%3D (Pubitemid 46426485)
130. F Turnbull B Neal C Algert J Chalmers N Chapman J Cutler M Woodward S MacMahon Blood Pressure Lowering Treatment Trialists' Collaboration 2005 Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials Arch Intern Med 165 1410 1419 10.1001/archinte.165.12.1410 15983291 (Pubitemid 40973424)
131. A Tuttolomondo A Pinto G Salemi D Di Raimondo R Di Sciacca P Fernandez P Ragonese G Savettieri G Licata 2008 Diabetic and non-diabetic subjects with ischemic stroke: differences, subtype distribution and outcome Nutr Metab Cardiovasc Dis 18 152 157 10.1016/j.numecd.2007.02.003 17702553 (Pubitemid 351282470)
132. UKPDS Group 1998 Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) Lancet 352 854 865 10.1016/S0140-6736(98)07037-8 (Pubitemid 28416719)
133. UKPDS Group 1998 Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39 BMJ 317 713 720
134. UKPDS Group 1998 Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) Lancet 352 837 853 10.1016/S0140- 6736(98)07019-6 (Pubitemid 28416718)
135. UKPDS Group 1998 Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38 BMJ 317 703 713
136. US Department of Health and Human Services National Heart, Lung and Blood Institute (2004) The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. NIH Publication No. 04-5230 (Available at: http://www.nhlbi.nih.gov/guidelines/ hypertension/. Last accessed 1 April 2009)
137. J Vivancos-Mora AC Gil-Núñez 2005 Lipids and stroke: the opportunity of lipid-lowering treatment Cerebrovasc Dis 20 Suppl 2 53 67 10.1159/000089357 16327254 1:CAS:528:DC%2BD2MXht1OqtrvO (Pubitemid 44689460)
138. C Wanner V Krane W März M Olschewski JF Mann G Ruf E Ritz German Diabetes Dialysis Study Investigators 2005 Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis N Engl J Med 353 238 248 10.1056/NEJMoa043545 16034009 1:CAS:528:DC%2BD2MXmt1Kms7s%3D (Pubitemid 41058323)
139. C Watala M Boncler P Gresner 2005 Blood platelet abnormalities and pharmacological modulation of platelet reactivity in patients with diabetes mellitus Pharmacol Rep 57 suppl 42 58 16415486
140. PK Whelton J Barzilay WC Cushman 2005 Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Arch Intern Med 165 1401 1409 10.1001/archinte.165.12.1401 15983290 1:CAS:528:DC%2BD2MXmsFylurs%3D (Pubitemid 40973423)
141. R Wilcox MG Bousser DJ Betteridge G Schernthaner V Pirags S Kupfer J Dormandy PROactive Investigators 2007 Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04) Stroke 38 865 873 10.1161/01.STR.0000257974.06317.49 17290029 1:CAS:528: DC%2BD2sXhslygur8%3D (Pubitemid 46568445)
142. M Woodward X Zhang F Barzi W Pan H Ueshima A Rodgers S MacMahon Asia Pacific Cohort Studies Collaboration 2003 The effects of diabetes on the risks of major cardiovascular diseases and death in the Asia-Pacific region Diabetes Care 26 360 366 10.2337/diacare.26.2.360 12547863 1:STN:280: DC%2BD3s%2Fntl2qtA%3D%3D (Pubitemid 36929056)
143. RX You JJ McNeil HM O'Malley SM Davis AG Thrift GA Donnan 1997 Risk factors for stroke due to cerebral infarction in young adults Stroke 28 1913 1918 9341695 1:STN:280:DyaK1c%2FgtV2jsA%3D%3D
144. Y Yui T Sumiyoshi K Kodama A Hirayama H Nonogi K Kanmatsuse H Origasa O Iimura M Ishii T Saruta K Arakawa S Hosoda C Kawai 2004 Nifedipine retard was as effective as angiotensin converting enzyme inhibitors in preventing cardiac events in high-risk hypertensive patients with diabetes and coronary artery disease: the Japan Multicenter Investigation for Cardiovascular Diseases-B (JMIC-B) subgroup analysis Hypertens Res 27 449 456 10.1291/hypres.27.449 15302980 1:CAS:528:DC%2BD2cXot1Olu7Y%3D (Pubitemid 39157546)
145. S Yusuf HC Diener RL Sacco D Cotton S Ounpuu WA Lawton Y Palesch RH Martin GW Albers P Bath N Bornstein BP Chan ST Chen L Cunha B Dahlöf J De Keyser GA Donnan C Estol P Gorelick V Gu K Hermansson L Hilbrich M Kaste C Lu T Machnig P Pais R Roberts V Skvortsova P Teal D Toni C VanderMaelen T Voigt M Weber BW Yoon PRoFESS Study Group 2008 Telmisartan to prevent recurrent stroke and cardiovascular events N Engl J Med 359 1225 1237 10.1056/NEJMoa0804593 18753639 1:CAS:528:DC%2BD1cXhtFGjur3O
146. CX Zhao YH Cui Q Fan PH Wang R Hui K Cianflone DW Wang 2009 Small dense low-density lipoproteins and associated risk factors in patients with stroke Cerebrovasc Dis 27 99 104 10.1159/000175768 19033685 1:CAS:528: DC%2BD1MXntVGrsg%3D%3D
147. Y Zhao A Patzer T Herdegen P Gohlke J Culman 2006 Activation of cerebral peroxisome proliferator-activated receptors gamma promotes neuroprotection by attenuation of neuronal cyclooxygenase-2 overexpression after focal cerebral ischemia in rats FASEB J 20 1162 1175 10.1096/fj.05-5007com 16770015 1:CAS:528:DC%2BD28XlvFSns7w%3D (Pubitemid 44943912)